A team of researchers at Roswell Park Comprehensive Cancer Center, led by Dhyan Chandra, PhD, has discovered a new therapeutic target for neuroendocrine prostate cancer, a rare and hard-to-treat form of prostate cancer.

Governor Kathy Hochul celebrated the opening of the Roswell Park GMP Engineering and Cell Manufacturing Facility, New York's first cell and gene therapy hub, located at Roswell Park Comprehensive Cancer Center in Buffalo.

Roswell Park has launched registration for the fifth annual IceCycle fundraising event, co-presented by Highmark Blue Cross Blue Shield and the West Herr Automotive Group.

A study led by Roswell Park provides new insight into the complex interactions of the “tumor-immune-gut axis,” and its role in influencing immunotherapy responses in patients with recurrent ovarian cancer. Newly published in Nature Communications, the findings emphasize the role of the patient’s microbiome — the collection of microorganisms in the body —and lay the groundwork for future clinical trials aimed at improving treatment outcomes.

Among the highlights of Roswell Park presentations at the 2024 San Antonio Breast Cancer Symposium are a special session moderated by Christine Ambrosone, PhD, focused on helping patients and survivors to cut through the confusion and conflicting evidence on exercise and lifestyle factors.

About a third of patients with diffuse large B cell lymphoma (DLBCL), a fast-growing form of lymphoma, will see their disease advance or recur following treatment. Seeking a new treatment strategy that might boost the effectiveness of existing DLBCL therapies, a team from Roswell Park has been working to understand the underlying mechanisms of the targeted chemotherapy venetoclax.